Review: what to do when all RBCs are incompatible—serologic aspects

Nance, Sandra; Arndt, Patricia A.

doi:10.21307/immunohematology-2019-441

Cited by 6 publications

(1 citation statement)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though the latter point plays a key role in case of massive blood loss and blood transfusion, it has not yet been considerably evaluated. The vast majority, if not all, of recommendations stress the holding rather than transfusion of incompatible RBCs, even in emergency cases and life-threatening blood loss [ 12 , 13 , 14 , 15 , 16 , 17 ]. Based on our experience, detectable alloantibodies should not represent a contraindication in patients with massive bleeding as long as bleeding has not been stopped.…”

Section: Introductionmentioning

confidence: 99%

Safety of Uncrossmatched ABO-Compatible RBCs in Alloimmunized Patients with Bleeding: Data from Two Decades: Results of a Systematic Analysis in 6,109 Patients

Ringel

Schoenfeld

Bali

et al. 2021

Transfus Med Hemother

View full text Add to dashboard Cite

Introduction: Uncrossmatched ABO-compatible red blood cells (RBCs) are generally recommended in patients with life-threatening massive bleeding. There is little data regarding RBC transfusion when patients are transfused against clinically significant alloantibodies because compatible RBCs are not immediately available. Methods/Patients: All patients reviewed in this study (n = 6,109) required emergency blood transfusion and were treated at the Charité – Universitätsmedizin Berlin between 2001 and 2015. Primary uncrossmatched O Rh(D)-positive or -negative RBC units were immediately transfused prior to complete regulatory serological testing including determination of ABO group, Rhesus antigens, antibody screening, and crossmatching. Results: Without any significant change in the protocol of emergency transfusion of RBCs, a total of 63,373 RBC units were transfused in 6,109 patients. Antibody screening was positive in 413 patients (6.8%), and 19 of these patients received RBC units against clinically significant alloantibodies. None of these patients appeared to have developed significant hemolysis, and only one patient with anti-D seems to have developed signs of insignificant hemolysis following the transfusion of three Rh(D)-positive units. One patient who had anti-Jka received unselected units and did not develop a hemolytic transfusion reaction. Conclusion: Transfusion of uncrossmatched ABO-compatible RBCs against alloantibodies is highly safe in patients with life-threatening hemorrhage.

show abstract